Neurocutaneous Syndromes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major neurocutaneous syndromes markets are expected to exhibit a CAGR of 6.63% during 2024-2034
The neurocutaneous syndromes market has been comprehensively analyzed in IMARC's new report titled "Neurocutaneous Syndromes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neurocutaneous syndromes refer to a group of genetic disorders that affect the nervous system and manifest as various skin abnormalities. These diseases commonly result from mutations in genes that play key roles in the development and function of both neural and skin tissues. The symptoms are quite diverse but generally involve cutaneous manifestations, including birthmarks, tumors, or patches of discolored skin, along with neurological issues, such as seizures, developmental delays, or intellectual disabilities. Some syndromes may also be associated with vision problems, hearing loss, and even malignancies like cancer. Skin abnormalities are often the most visible signs and can sometimes provide clues leading to a diagnosis. The diagnosis of neurocutaneous syndromes typically involves a combination of clinical evaluation, genetic testing, and imaging studies, such as MRIs or CT scans. Physicians will look for characteristic physical signs and symptoms, as well as family history. Genetic analysis can confirm the presence of specific gene variations associated with these syndromes.
The increasing prevalence of somatic mutations within the GNAQ gene that can lead to abnormal growth of neural tissue and blood vessels, predominantly affecting the nervous system and skin, is primarily driving the neurocutaneous syndromes market. In addition to this, the inflating utilization of multidisciplinary approaches encompassing physical and occupational therapies, since they help in enhancing motor skills, ameliorating muscle strength, and refining coordination, is also creating a positive outlook for the market. Moreover, the widespread adoption of innovative laser techniques, such as pulsed dye lasers, aimed at selectively targeting and neutralizing abnormal blood vessels within the skin, is further bolstering the market growth. Apart from this, the rising usage of effective medications like beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs to alleviate symptoms and enhance the quality of life for individuals suffering from neurocutaneous syndromes is acting as another significant growth-inducing factor. Additionally, the emerging popularity of telemedicine services for remote monitoring and consultation, thereby making healthcare more accessible, is also augmenting the market growth. Furthermore, the escalating demand for genetic modification techniques, including CRISPR and zinc finger nucleases, which work by correcting the pathogenic mutations underlying these conditions, is expected to drive the neurocutaneous syndromes market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the neurocutaneous syndromes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neurocutaneous syndromes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neurocutaneous syndromes market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neurocutaneous syndromes market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neurocutaneous syndromes market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neurocutaneous syndromes marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neurocutaneous syndromes market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neurocutaneous syndromes market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neurocutaneous syndromes market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neurocutaneous syndromes across the seven major markets?
What is the number of prevalent cases (2018-2034) of neurocutaneous syndromes by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neurocutaneous syndromes by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neurocutaneous syndromes across the seven major markets?
What is the size of the neurocutaneous syndromes patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neurocutaneous syndromes?
What will be the growth rate of patients across the seven major markets?
Neurocutaneous Syndromes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neurocutaneous syndromes drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neurocutaneous syndromes market?
What are the key regulatory events related to the neurocutaneous syndromes market?
What is the structure of clinical trial landscape by status related to the neurocutaneous syndromes market?
What is the structure of clinical trial landscape by phase related to the neurocutaneous syndromes market?
What is the structure of clinical trial landscape by route of administration related to the neurocutaneous syndromes market?
The neurocutaneous syndromes market has been comprehensively analyzed in IMARC's new report titled "Neurocutaneous Syndromes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neurocutaneous syndromes refer to a group of genetic disorders that affect the nervous system and manifest as various skin abnormalities. These diseases commonly result from mutations in genes that play key roles in the development and function of both neural and skin tissues. The symptoms are quite diverse but generally involve cutaneous manifestations, including birthmarks, tumors, or patches of discolored skin, along with neurological issues, such as seizures, developmental delays, or intellectual disabilities. Some syndromes may also be associated with vision problems, hearing loss, and even malignancies like cancer. Skin abnormalities are often the most visible signs and can sometimes provide clues leading to a diagnosis. The diagnosis of neurocutaneous syndromes typically involves a combination of clinical evaluation, genetic testing, and imaging studies, such as MRIs or CT scans. Physicians will look for characteristic physical signs and symptoms, as well as family history. Genetic analysis can confirm the presence of specific gene variations associated with these syndromes.
The increasing prevalence of somatic mutations within the GNAQ gene that can lead to abnormal growth of neural tissue and blood vessels, predominantly affecting the nervous system and skin, is primarily driving the neurocutaneous syndromes market. In addition to this, the inflating utilization of multidisciplinary approaches encompassing physical and occupational therapies, since they help in enhancing motor skills, ameliorating muscle strength, and refining coordination, is also creating a positive outlook for the market. Moreover, the widespread adoption of innovative laser techniques, such as pulsed dye lasers, aimed at selectively targeting and neutralizing abnormal blood vessels within the skin, is further bolstering the market growth. Apart from this, the rising usage of effective medications like beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs to alleviate symptoms and enhance the quality of life for individuals suffering from neurocutaneous syndromes is acting as another significant growth-inducing factor. Additionally, the emerging popularity of telemedicine services for remote monitoring and consultation, thereby making healthcare more accessible, is also augmenting the market growth. Furthermore, the escalating demand for genetic modification techniques, including CRISPR and zinc finger nucleases, which work by correcting the pathogenic mutations underlying these conditions, is expected to drive the neurocutaneous syndromes market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the neurocutaneous syndromes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neurocutaneous syndromes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neurocutaneous syndromes market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neurocutaneous syndromes market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neurocutaneous syndromes market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neurocutaneous syndromes marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the neurocutaneous syndromes market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neurocutaneous syndromes market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neurocutaneous syndromes market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neurocutaneous syndromes across the seven major markets?
What is the number of prevalent cases (2018-2034) of neurocutaneous syndromes by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neurocutaneous syndromes by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neurocutaneous syndromes across the seven major markets?
What is the size of the neurocutaneous syndromes patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neurocutaneous syndromes?
What will be the growth rate of patients across the seven major markets?
Neurocutaneous Syndromes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neurocutaneous syndromes drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neurocutaneous syndromes market?
What are the key regulatory events related to the neurocutaneous syndromes market?
What is the structure of clinical trial landscape by status related to the neurocutaneous syndromes market?
What is the structure of clinical trial landscape by phase related to the neurocutaneous syndromes market?
What is the structure of clinical trial landscape by route of administration related to the neurocutaneous syndromes market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROCUTANEOUS SYNDROMES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROCUTANEOUS SYNDROMES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROCUTANEOUS SYNDROMES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (???2018-2034)
7.2.4 Epidemiology by Gender (???2018-2034)
7.2.5 Diagnosed Cases (???2018-2034)
7.2.6 Patient Pool/Treated Cases (???2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (???2018-2034)
7.3.4 Epidemiology by Gender (???2018-2034)
7.3.5 Diagnosed Cases (???2018-2034)
7.3.6 Patient Pool/Treated Cases (???2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (???2018-2034)
7.4.4 Epidemiology by Gender (???2018-2034)
7.4.5 Diagnosed Cases (???2018-2034)
7.4.6 Patient Pool/Treated Cases (???2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (???2018-2034)
7.5.4 Epidemiology by Gender (???2018-2034)
7.5.5 Diagnosed Cases (???2018-2034)
7.5.6 Patient Pool/Treated Cases (???2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (???2018-2034)
7.6.4 Epidemiology by Gender (???2018-2034)
7.6.5 Diagnosed Cases (???2018-2034)
7.6.6 Patient Pool/Treated Cases (???2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (???2018-2034)
7.7.4 Epidemiology by Gender (???2018-2034)
7.7.5 Diagnosed Cases (???2018-2034)
7.7.6 Patient Pool/Treated Cases (???2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (???2018-2034)
7.8.4 Epidemiology by Gender (???2018-2034)
7.8.5 Diagnosed Cases (???2018-2034)
7.8.6 Patient Pool/Treated Cases (???2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (???2018-2034)
7.9.4 Epidemiology by Gender (???2018-2034)
7.9.5 Diagnosed Cases (???2018-2034)
7.9.6 Patient Pool/Treated Cases (???2018-2034)
8 NEUROCUTANEOUS SYNDROMES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROCUTANEOUS SYNDROMES - UNMET NEEDS
10 NEUROCUTANEOUS SYNDROMES - KEY ENDPOINTS OF TREATMENT
11 NEUROCUTANEOUS SYNDROMES - MARKETED PRODUCTS
11.1 List of Neurocutaneous Syndromes Marketed Drugs Across the Top 7 Markets
11.1.1 Koselugo (Selumetinib)- AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Epidiolex (Cannabidiol) - GW Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Afinitor (Everolimus) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Hyftor (Sirolimus Topical Gel) - Nobelpharma America
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 NEUROCUTANEOUS SYNDROMES - PIPELINE DRUGS
12.1 List of Neurocutaneous Syndromes Pipeline Drugs Across the Top 7 Markets
12.1.1 Ganaxolone - Marinus Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 QLS-101 - Qlaris Bio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 NFX-179 gel - NFlection Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 FCN-159 - Fosun Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 NPC-12Y - Nobelpharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13 NEUROCUTANEOUS SYNDROMES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NEUROCUTANEOUS SYNDROMES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROCUTANEOUS SYNDROMES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neurocutaneous Syndromes - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neurocutaneous Syndromes - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neurocutaneous Syndromes - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neurocutaneous Syndromes - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neurocutaneous Syndromes - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neurocutaneous Syndromes - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neurocutaneous Syndromes - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neurocutaneous Syndromes - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neurocutaneous Syndromes - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neurocutaneous Syndromes - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neurocutaneous Syndromes - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neurocutaneous Syndromes - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neurocutaneous Syndromes - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neurocutaneous Syndromes - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neurocutaneous Syndromes - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neurocutaneous Syndromes - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
16 NEUROCUTANEOUS SYNDROMES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROCUTANEOUS SYNDROMES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROCUTANEOUS SYNDROMES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEUROCUTANEOUS SYNDROMES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEUROCUTANEOUS SYNDROMES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEUROCUTANEOUS SYNDROMES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (???2018-2034)
7.2.4 Epidemiology by Gender (???2018-2034)
7.2.5 Diagnosed Cases (???2018-2034)
7.2.6 Patient Pool/Treated Cases (???2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (???2018-2034)
7.3.4 Epidemiology by Gender (???2018-2034)
7.3.5 Diagnosed Cases (???2018-2034)
7.3.6 Patient Pool/Treated Cases (???2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (???2018-2034)
7.4.4 Epidemiology by Gender (???2018-2034)
7.4.5 Diagnosed Cases (???2018-2034)
7.4.6 Patient Pool/Treated Cases (???2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (???2018-2034)
7.5.4 Epidemiology by Gender (???2018-2034)
7.5.5 Diagnosed Cases (???2018-2034)
7.5.6 Patient Pool/Treated Cases (???2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (???2018-2034)
7.6.4 Epidemiology by Gender (???2018-2034)
7.6.5 Diagnosed Cases (???2018-2034)
7.6.6 Patient Pool/Treated Cases (???2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (???2018-2034)
7.7.4 Epidemiology by Gender (???2018-2034)
7.7.5 Diagnosed Cases (???2018-2034)
7.7.6 Patient Pool/Treated Cases (???2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (???2018-2034)
7.8.4 Epidemiology by Gender (???2018-2034)
7.8.5 Diagnosed Cases (???2018-2034)
7.8.6 Patient Pool/Treated Cases (???2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (???2018-2034)
7.9.4 Epidemiology by Gender (???2018-2034)
7.9.5 Diagnosed Cases (???2018-2034)
7.9.6 Patient Pool/Treated Cases (???2018-2034)
8 NEUROCUTANEOUS SYNDROMES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEUROCUTANEOUS SYNDROMES - UNMET NEEDS
10 NEUROCUTANEOUS SYNDROMES - KEY ENDPOINTS OF TREATMENT
11 NEUROCUTANEOUS SYNDROMES - MARKETED PRODUCTS
11.1 List of Neurocutaneous Syndromes Marketed Drugs Across the Top 7 Markets
11.1.1 Koselugo (Selumetinib)- AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Epidiolex (Cannabidiol) - GW Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Afinitor (Everolimus) - Novartis
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Hyftor (Sirolimus Topical Gel) - Nobelpharma America
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 NEUROCUTANEOUS SYNDROMES - PIPELINE DRUGS
12.1 List of Neurocutaneous Syndromes Pipeline Drugs Across the Top 7 Markets
12.1.1 Ganaxolone - Marinus Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 QLS-101 - Qlaris Bio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 NFX-179 gel - NFlection Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 FCN-159 - Fosun Pharmaceutical
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 NPC-12Y - Nobelpharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13 NEUROCUTANEOUS SYNDROMES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NEUROCUTANEOUS SYNDROMES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEUROCUTANEOUS SYNDROMES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neurocutaneous Syndromes - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neurocutaneous Syndromes - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neurocutaneous Syndromes - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neurocutaneous Syndromes - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neurocutaneous Syndromes - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neurocutaneous Syndromes - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neurocutaneous Syndromes - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neurocutaneous Syndromes - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neurocutaneous Syndromes - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neurocutaneous Syndromes - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neurocutaneous Syndromes - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neurocutaneous Syndromes - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neurocutaneous Syndromes - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neurocutaneous Syndromes - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neurocutaneous Syndromes - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neurocutaneous Syndromes - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neurocutaneous Syndromes - Access and Reimbursement Overview
16 NEUROCUTANEOUS SYNDROMES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEUROCUTANEOUS SYNDROMES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEUROCUTANEOUS SYNDROMES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
